drugset
drugset / Trial / NCT02272270

Phase I Newly Diagnosed GBM With Temozolomide, Radiation, and Minocycline Followed by Adjuvant Minocycline/Temozolomide (D-TERMINED)

NCT02272270 ↗

Phase 1 Completed 25 enrolled University of Utah
NaSingle-groupOpen-labelTreatment

Summary

This will be an open label, single arm study. Subjects with newly diagnosed high grade glioma will begin minocycline one week prior to beginning postoperative chemoradiation and continue it until progression, intolerance, or the end of adjuvant temozolomide, whichever comes first.

Timeline

Start
2014-10-27
Primary completion
2017-03-08
Completion
2018-02-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Minocycline Small molecule 100 mg Oral
Subject Minocycline Small molecule 150 mg Oral
Subject Minocycline Small molecule 200 mg Oral
Subject Minocycline Small molecule 300 mg Oral
Subject Minocycline Small molecule 400 mg Oral
Background Temozolomide Small molecule 150 mg/m2 —
Background Temozolomide Small molecule 200 mg/m2 —

Indications

glioma